Japan Genome Editing Market To Reach $1.45 Billion By 2033

Japan Genome Editing Market Growth & Trends

The Japan genome editing market size is projected to reach USD 1.45 billion by 2033, growing at a CAGR of 17.97% from 2025 to 2033, according to a new report by Grand View Research, Inc. The Japan genome editing market is witnessing robust expansion, propelled by increasing investment in precision medicine, regenerative therapies, and agricultural biotechnology. The growing focus on next-generation therapeutics, particularly gene therapies, rare disease treatments, and personalized oncology solutions, fuels demand for advanced genome editing technologies such as CRISPR-Cas9, TALENs, and base editors. Regulatory encouragement and supportive government initiatives, including funding for biotech innovation and streamlining of clinical approval processes, further accelerate market momentum.

A strong academic and research infrastructure and the presence of globally recognized institutions underpin innovation and collaboration across sectors. Pharmaceutical companies, biotech startups, and educational consortia are increasingly converging to translate gene editing breakthroughs into viable clinical and commercial applications. Japan’s aging population and rising incidence of chronic genetic disorders are also driving urgency around genome-targeted interventions, catalyzing demand for safe, effective, and scalable editing platforms.

Technological advancements in delivery systems, precision targeting, and off-target risk mitigation are expanding genome editing's therapeutic applicability. Integration with digital tools and AI-driven bioinformatics platforms is improving target discovery, optimizing design workflows, and accelerating preclinical development. In agriculture and food biotechnology, gene editing is applied to develop disease-resistant, high-yield crops, aligning with national food security and sustainability goals.

With cross-sector partnerships, increased R&D activity, and supportive policy frameworks, the Japan genome editing market is well-positioned to play a leading role in shaping the future of precision biotechnology. Strategic alliances, localized manufacturing, and a growing IP portfolio reinforce Japan's position as a key hub for genome editing innovation in therapeutic and non-therapeutic applications.

 Request a free sample copy or view report summary: Japan Genome Editing Market Report

Japan Genome Editing Market Report Highlights

• By technology, CRISPR/Cas9 dominated the Japan genome editing market with a market share of 44.14% in 2024. This dominance stems from CRISPR/Cas9’s superior efficiency, precision, and cost-effectiveness in targeted genome modifications. Its widespread adoption across research institutes, biotech startups, and pharmaceutical companies reflects its ability to accelerate functional genomics studies, therapeutic development, and agricultural innovation. The relatively easier design and scalability of CRISPR/Cas9 tools make them the preferred choice for both in vitro and in vivo applications.

• By delivery method, in vivo genome editing led the market with a market share of 50.63% in 2024, driven by rising investments in gene therapy and regenerative medicine, especially for treating inherited diseases and cancers. Japan’s advanced healthcare infrastructure and focus on curative therapies have fueled the development of novel delivery platforms, such as lipid nanoparticles and adeno-associated viral vectors (AAVs), enabling more effective gene transfer in living organisms. The ability to directly edit genes within the patient offers transformative potential and continues to attract clinical trial activity and investment.

• By application, genetic engineering emerged as the leading segment, with a market share of 73.16% in 2024, contributing the highest revenue share. The segment’s growth is driven by Japan’s commitment to disease modeling, therapeutic discovery, and functional genomics research. Genetic engineering is widely used across academia and industry to develop customized cell lines, engineer model organisms, and advance gene therapy pipelines. It also plays a crucial role in precision breeding for agriculture and aquaculture, which are strategic sectors in Japan’s biotech innovation agenda.

• By mode, the contract segment held the largest share of 66.77% in 2024, as outsourcing genome editing services becomes increasingly common among biotech startups and research institutions. Contract service providers offer specialized expertise, infrastructure, and regulatory support, allowing innovators to reduce time-to-market and control development costs. Japan’s strong contract research and manufacturing organization ecosystem supports gene editing across preclinical, clinical, and commercial phases.

• By end use, biotechnology and pharmaceutical companies dominated the Japan genome editing market with a share of 49.66% in 2024. These companies leverage genome editing to accelerate drug discovery, develop gene and cell therapies, and explore novel treatment modalities for complex diseases. With robust R&D pipelines and increasing government incentives, these end users are at the forefront of innovation. Collaborations with academic institutions and global biotech firms further strengthen their position, making them central players in the commercial Application of genome editing technologies.

• In January 2025, Takara?Bio USA Holdings, Inc. completed the acquisition of California?based Curio Bioscience, integrating its Trekker and Seeker spatial?biology platforms into its U.S. single?cell omics portfolio. 

Japan Genome Editing Market Segmentation

Grand View Research has segmented the Japan genome editing market on the basis of technology, delivery method, application, mode, and end use:

Japan Genome Editing Technology Outlook (Revenue, USD Million, 2021 - 2033)

• (CRISPR)/Cas9

• TALENs/MegaTALs

• ZFN

• Meganucleases

• Others

Japan Genome Editing Delivery Method Outlook (Revenue, USD Million, 2021 - 2033)

• Ex-vivo

• In-vivo

Japan Genome Editing Application Outlook (Revenue, USD Million, 2021 - 2033)

• Genetic Engineering

  • Cell line engineering

  • Animal genetic engineering

  • Plant genetic engineering

  • Others

• Clinical Applications

  • Diagnostics Development

  • Therapy Development

Japan Genome Editing Mode Outlook (Revenue, USD Million, 2021 - 2033)

• Contract

• In-house

Japan Genome Editing End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Biotechnology and pharmaceutical companies

• Academic and government research institutes

• Contract research organizations

List of Key Players in the Japan Genome Editing Market

• Merck KGaA

• Takara Bio Inc.

• Revvity, Inc.

• Danaher Corporation

• GenScript

• New England Biolabs

• Lonza

• Thermo Fisher Scientific, Inc.

• Charles River Laboratories

• Eurofins Scientific